论文部分内容阅读
目的观察孟鲁司特钠在小儿哮喘治疗中的临床应用效果。方法随机抽取医院2012年10月-2015年12月收治的哮喘患儿120例,将所有患儿随机分为观察组和对照组,每组60例,对照组采用布地奈德吸入治疗,观察组在对照组的基础上加服孟鲁司特钠治疗,比较2组患儿肺功能变化、治疗效果及不良反应发生率。结果 2组治疗前用力肺活量占预计值的百分比(FVC%)、呼吸峰流量占预计值的百分比(PEF%)及第1秒用力呼吸末容积占预计值的百分比(FEV_1%)比较无显著性差异(P>0.05),治疗后2组FVC%、PEF%及FEV_1%均高于治疗前,且观察组高于对照组,差异均有统计学意义(P<0.05),观察组总有效率为98.33%高于对照组的80.00%,差异有统计学意义(P<0.05)。观察组不良反应发生率为1.67%低于对照组的5.00%,差异有统计学意义(P<0.05)。结论孟鲁司特钠在小儿哮喘治疗中的临床应用效果显著,可使患儿的肺功能指标得到有效改善,提高治疗效果的同时,有助于减轻患儿的疼痛感,提高患儿的生活质量,值得临床推广。
Objective To observe the clinical effect of montelukast sodium in the treatment of pediatric asthma. Methods A total of 120 asthmatic children were randomly selected in the hospital from October 2012 to December 2015. All the children were randomly divided into observation group and control group, 60 cases in each group. The control group was treated with budesonide inhalation. The observation group On the basis of the control group plus Montelukast sodium treatment, two groups of children with pulmonary function changes, the treatment effect and the incidence of adverse reactions. Results Before treatment, the ratio of predicted forced vital capacity (FVC%), percentage of predicted peak respiratory flow (PEF%) and percentage of predicted end-expiratory volume in 1 second (FEV_1%) were not significant (P> 0.05). The FVC%, PEF% and FEV_1% of two groups after treatment were higher than those before treatment, and the difference between the two groups was statistically significant (P <0.05). The total effective rate 98.33% higher than the control group 80.00%, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 1.67% lower than that in the control group (5.00%), the difference was statistically significant (P <0.05). Conclusion Montelukast sodium in children with asthma in the clinical treatment of significant effect, can make children’s lung function indicators can be effectively improved to improve the therapeutic effect, while helping to reduce the pain in children and improve the lives of children Quality, it is worth clinical promotion.